- Home
- ANAB
ANAB
AnaptysBio Inc.
as 07-05-2024 1:30pm EST
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, our PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, our BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).
| Founded: | 2005 | Country: | United States |
| Employees: | N/A | City: | SAN DIEGO |
| Market Cap: | 681.9M | IPO Year: | 2017 |
| Target Price: | $46.38 | AVG Volume (30 days): | 346.0K |
| Analyst Decision: | Buy | Number of Analysts: | 8 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -6.14 | EPS Growth: | N/A |
| 52 Week Low/High: | $13.36 - $27.50 | Next Earning Date: | 08-05-2024 |
| Revenue: | $22,962,000 | Revenue Growth: | 114.78% |
| Revenue Growth (this year): | 153.16% | Revenue Growth (next year): | -54.52% |
Stock Insider Trading Activity of AnaptysBio Inc. (ANAB)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| FENTON DENNIS M | ANAB | Director | Jun 21 '24 | Sell | $23.17 | 1,950 | $45,181.50 | 1,950 | SEC Form 4 |
| RENTON HOLLINGS | ANAB | Director | Jun 15 '24 | Sell | $23.16 | 1,950 | $45,162.00 | 1,950 | SEC Form 4 |
| MULROY DENNIS | ANAB | CHIEF FINANCIAL OFFICER | May 22 '24 | Sell | $23.72 | 1,500 | $35,580.00 | 964 | SEC Form 4 |
| Faga Daniel | ANAB | CEO | Mar 22 '24 | Sell | $22.78 | 145,940 | $3,325,184.52 | 752,087 | SEC Form 4 |
| Faga Daniel | ANAB | CEO | Mar 22 '24 | Sell | $21.42 | 3,000 | $64,267.50 | 749,087 | SEC Form 4 |
| LOUMEAU ERIC J | ANAB | CHIEF LEGAL OFFICER | Feb 16 '24 | Sell | $25.00 | 5,000 | $125,000.00 | 3,240 | SEC Form 4 |
| MULROY DENNIS | ANAB | CHIEF FINANCIAL OFFICER | Jan 30 '24 | Sell | $23.63 | 3,065 | $72,425.34 | 964 | SEC Form 4 |
| Lizzul Paul F. | ANAB | Chief Medical Officer | Jan 6 '24 | Sell | $21.81 | 2,554 | $55,702.74 | 10,118 | SEC Form 4 |
| LOUMEAU ERIC J | ANAB | Chief Legal Officer | Jan 6 '24 | Sell | $21.81 | 2,305 | $50,272.05 | 3,240 | SEC Form 4 |
| MULROY DENNIS | ANAB | Chief Financial Officer | Jan 6 '24 | Sell | $21.81 | 2,180 | $47,545.80 | 4,029 | SEC Form 4 |
| Faga Daniel | ANAB | CEO | Jan 6 '24 | Sell | $21.81 | 6,866 | $149,747.46 | 898,027 | SEC Form 4 |
| LOUMEAU ERIC J | ANAB | Chief Legal Officer | Nov 22 '23 | Sell | $14.19 | 882 | $12,515.58 | 0 | SEC Form 4 |
Latest AnaptysBio Inc. News
ANAB Breaking Stock News: Dive into ANAB Ticker-Specific Updates for Smart Investing
Zacks
11 days ago
Repligen (RGEN) Soars 4.4%: Is Further Upside Left in the Stock?
Simply Wall St.
a month ago
Industry Analysts Just Upgraded Their AnaptysBio, Inc. (NASDAQ:ANAB) Revenue Forecasts By 16%
Zacks
2 months ago
AnaptysBio, Inc. (ANAB) Reports Q1 Loss, Tops Revenue Estimates
GlobeNewswire
2 months ago
Anaptys Announces First Quarter 2024 Financial Results and Provides Business Update
GlobeNewswire
2 months ago
Anaptys Announces Positive Top-Line GEMINI-2 Phase 3 Clinical Trial Results of Imsidolimab (IL-36R) in Generalized Pustular Psoriasis (GPP)
GlobeNewswire
2 months ago
Anaptys to Receive $50 Million in a Capped Non-Recourse Monetization from Amended Agreement with Sagard in Exchange for Additional Jemperli Royalties
Zacks
2 months ago
AnaptysBio, Inc. (ANAB) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Zacks
2 months ago
AnaptysBio (ANAB) Soars 14.3%: Is Further Upside Left in the Stock?
Share on Social Networks:
Disclaimer
The information presented on this page, "ANAB AnaptysBio Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.